
Immune Regulation makes Peter Greenleaf chairman and assembles a quintet of new execs; Bob Coughlin moves on from MassBio to JLL
→ In September, Immune Regulation raked in $53.4 million in a Series B for two programs in rheumatoid arthritis and asthma. This week, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.